123 related articles for article (PubMed ID: 35551376)
1. Low-Dose MST-16/VP-16 Combination Chemotherapy in 9 Patients with Tumor Stage Mycosis Fungoides.
Kato Y; Fukuhara Y; Nagatani T; Kanzaki A; Mae KI; Irisawa R; Harada K; Umebayashi Y; Tsuboi R
Dermatology; 2022; 238(5):961-966. PubMed ID: 35551376
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy in the tumour stage of mycosis fungoides with cyclophosphamide, vincristine, vp-16, adriamycin and prednisolone (cop, chop, cavop): a report from the Scandinavian mycosis fungoides study group.
Molin L; Thomsen K; Volden G; Groth O; Hellbe L; Holst R; Knudsen EA; Roupe G; Schmidt H
Acta Derm Venereol; 1980; 60(6):542-4. PubMed ID: 6162347
[TBL] [Abstract][Full Text] [Related]
3. Etoposide as a single agent in the treatment of mycosis fungoides: A retrospective analysis.
Purnak S; Azar J; Mark LA
Dermatol Ther; 2018 Mar; 31(2):e12586. PubMed ID: 29316111
[TBL] [Abstract][Full Text] [Related]
4. A case-control study of clinicopathologic features, prognosis, and therapeutic responses in patients with granulomatous mycosis fungoides.
Li JY; Pulitzer MP; Myskowski PL; Dusza SW; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2013 Sep; 69(3):366-74. PubMed ID: 23685027
[TBL] [Abstract][Full Text] [Related]
5. Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides.
Hu JK; Carlson K; Girardi M
Yale J Biol Med; 2020 Mar; 93(1):41-44. PubMed ID: 32226334
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoides.
Wieser I; Wang C; Alberti-Violetti S; Lyons G; Tran C; Talpur R; Duvic M
Arch Dermatol Res; 2017 Aug; 309(6):453-459. PubMed ID: 28516243
[TBL] [Abstract][Full Text] [Related]
7. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
8. The use of interferon-α2a as monotherapy in stage IB patients with mycosis fungoides: A retrospective chart review of patient outcomes.
Gökşin Ş; İmren IG; Cenk H; Kaçar N; Duygulu Ş
Dermatol Ther; 2022 Apr; 35(4):e15344. PubMed ID: 35094466
[TBL] [Abstract][Full Text] [Related]
9. Mycosis fungoides associated with B-cell malignancies.
Barzilai A; Trau H; David M; Feinmesser M; Bergman R; Shpiro D; Schiby G; Rosenblatt K; Or R; Hodak E
Br J Dermatol; 2006 Aug; 155(2):379-86. PubMed ID: 16882178
[TBL] [Abstract][Full Text] [Related]
10. Epipodophyllotoxin (VP-16-213) in mycosis fungoides: A report from the Scandinavian mycosis fungoides study group.
Molin L; Thomsen K; Volden G; Bergqvist-Karlsson A; Hallberg O; Hellbe L
Acta Derm Venereol; 1979; 59(1):84-7. PubMed ID: 84480
[TBL] [Abstract][Full Text] [Related]
11. Interventions for mycosis fungoides.
Weberschock T; Strametz R; Lorenz M; Röllig C; Bunch C; Bauer A; Schmitt J
Cochrane Database Syst Rev; 2012 Sep; (9):CD008946. PubMed ID: 22972128
[TBL] [Abstract][Full Text] [Related]
12. Treatment of stage Ia and Ib mycosis fungoides with psoralen UVA monotherapy: an observational study in tertiary hospitals in the Canary Islands.
Hernández Z; Peñate Y; Hernández-Machín B; Pérez-Méndez L; Suárez-Hernández J; Hernández J; Fernández-de-Misa R
Int J Dermatol; 2014 Nov; 53(11):1417-22. PubMed ID: 24697305
[TBL] [Abstract][Full Text] [Related]
13. Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series.
Lewis DJ; Byekova YA; Emge DA; Duvic M
J Dermatolog Treat; 2017 Sep; 28(6):567-569. PubMed ID: 28635518
[TBL] [Abstract][Full Text] [Related]
14. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides.
Kakinuma T; Sugaya M; Nakamura K; Kaneko F; Wakugawa M; Matsushima K; Tamaki K
J Am Acad Dermatol; 2003 Jan; 48(1):23-30. PubMed ID: 12522366
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Low-Dose, Low-Frequency Oral Psoralen-UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides: A Randomized Clinical Trial.
Vieyra-Garcia P; Fink-Puches R; Porkert S; Lang R; Pöchlauer S; Ratzinger G; Tanew A; Selhofer S; Paul-Gunther S; Hofer A; Gruber-Wackernagel A; Legat F; Patra V; Quehenberger F; Cerroni L; Clark R; Wolf P
JAMA Dermatol; 2019 May; 155(5):538-547. PubMed ID: 30892603
[TBL] [Abstract][Full Text] [Related]
16. Leonine facies (LF) and mycosis fungoides (MF): A single-center study and systematic review of the literature.
Brown DN; Wieser I; Wang C; Dabaja BS; Duvic M
J Am Acad Dermatol; 2015 Dec; 73(6):976-86. PubMed ID: 26476898
[TBL] [Abstract][Full Text] [Related]
17. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis.
Kim YH; Jensen RA; Watanabe GL; Varghese A; Hoppe RT
Arch Dermatol; 1996 Nov; 132(11):1309-13. PubMed ID: 8915308
[TBL] [Abstract][Full Text] [Related]
18. Eosinophils in mycosis fungoides: an uncommon finding in the patch and plaque stages.
Dalton SR; Chandler WM; Abuzeid M; Hossler EW; Ferringer T; Elston DM; LeBoit PE
Am J Dermatopathol; 2012 Aug; 34(6):586-91. PubMed ID: 22814317
[TBL] [Abstract][Full Text] [Related]
19. Excimer laser in the treatment of mycosis fungoides.
Deaver D; Cauthen A; Cohen G; Sokol L; Glass F
J Am Acad Dermatol; 2014 Jun; 70(6):1058-60. PubMed ID: 24775402
[TBL] [Abstract][Full Text] [Related]
20. Juvenile mycosis fungoides: cutaneous T-cell lymphoma with frequent follicular involvement.
Hodak E; Amitay-Laish I; Feinmesser M; Davidovici B; David M; Zvulunov A; Pavlotsky F; Yaniv I; Avrahami G; Ben-Amitai D
J Am Acad Dermatol; 2014 Jun; 70(6):993-1001. PubMed ID: 24629999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
